Vasomotor Symptoms of Menopause

View All

Pharma News and Updates for Sarepta, Astellas, SiSaf, ImmPACT Bio, Otsuka, CytoAgents, Lundbeck
Sarepta Therapeutics’s SRP-9001 Gene Therapy; FDA Approves Astellas’ VEOZAH; FDA Orphan Drug Designation and Rare Pediatric Disease Designation to SiSaf’s siRNA Therapy SIS-101-ADO; FDA Grants Fast Track Designation to IMPT-314; FDA Approves First Drug for Agitation in People With Alzheimer’s Disease; FDA Accepted the CytoAgents’ IND Application for CTO1681

Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy Sarepta Therapeutics, Inc., a pioneer in precision genetic medicine for rare diseases, announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in favor of...

Find More

Vasomotor Symptoms of Menopause-Emerging Therapies

Vasomotor symptoms occur when a woman reaches the state of menopause and the ovaries stop producing eggs, resulting in the reduction of secretion of hormones such as estrogen and progesterone. Therapies available for vasomotor symptoms of menopause are hormonal and non-hormonal, where hormone therapy is the most eff...

Find More